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Abstract
Background: Statins are generally well-tolerated and serious side effects are infrequent, but some patients
experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly
specific, fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), which can
produce substantial and sustained reductions of low-density lipoprotein cholesterol (LDL-C).
Methods: The randomized, double-blind, placebo-controlled, parallel-group, phase 3 ODYSSEY NIPPON study will
explore alirocumab 150 mg every 4 weeks (Q4W) in 163 Japanese patients with hypercholesterolemia who are on
the lowest-strength dose of atorvastatin (5 mg/day) or are receiving a non-statin lipid-lowering therapy (LLT)
(fenofibrate, bezafibrate, ezetimibe, or diet therapy alone). Hypercholesterolemia is defined as LDL-C ≥ 100 mg/dL
(2.6 mmol/L) in patients with heterozygous familial hypercholesterolemia or non-familial hypercholesterolemia with
a history of documented coronary heart disease, or ≥120 mg/dL (3.1 mmol/L) in patients with non-familial
hypercholesterolemia classified as primary prevention category III (i.e. high-risk patients). During the 12-week
double-blind treatment period, patients will be randomized (1:1:1) to receive alirocumab subcutaneously (SC)
150 mg Q4W alternating with placebo for alirocumab Q4W, or alirocumab 150 mg SC every 2 weeks (Q2W), or SC
placebo Q2W. The primary efficacy endpoint is the percentage change in calculated LDL-C from baseline to week
12. The long-term safety and tolerability of alirocumab will also be investigated.
Discussion: The ODYSSEY NIPPON study will provide insights into the efficacy and safety of alirocumab 150 mg
Q4W or 150 mg Q2W among Japanese patients with hypercholesterolemia who are on the lowest-strength dose of
atorvastatin, or are receiving a non-statin LLT (including diet therapy alone).
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Background
Lowering low-density lipoprotein cholesterol (LDL-C)
levels is a cornerstone for the prevention of cardiovascu-
lar disease, the second leading cause of death in Japan
[1]. The Japan Atherosclerosis Society (JAS) guidelines
recommend lowering LDL-C to <100 mg/dL (2.6 mmol/
L) in patients with established cardiovascular disease, to
<100 mg/dL (or by 50% or more) in heterozygous famil-
ial hypercholesterolemia (heFH), and to <120 mg/dL
(3.1 mmol/L) in patients classified as category III in
primary prevention [2]. Patients in category III are
dyslipidaemic individuals with diabetes mellitus, non-
cardiogenic cerebral infarction, or peripheral artery
disease, and their 10-year absolute risk of coronary artery
disease death is ≥2%. The category also includes dyslipi-
daemic patients with low high-density lipoprotein
cholesterol (<40 mg/dL), and/or family history of prema-
ture coronary artery disease, and/or impaired glucose
tolerance, and their 10-year absolute risk of coronary
artery disease death is ≥0.5% and <2% [2].
Statins substantially reduce the risk of cardiovascular
morbidity and mortality [3] and are the preferred
treatment option for lowering LDL-C [2, 4, 5]. They are
generally well-tolerated and serious side effects are infre-
quent [6, 7], but some patients experience statin-
associated effects [6, 8–14] that result in dose reductions
or discontinuation of treatment [15].
Asian patients often show an increased response to
drug therapy when compared with Western populations,
leading to lower recommended doses of therapeutic
drugs [16]. The starting dose of atorvastatin is 10 mg/day
in both Japan and the United States, but the maximum
approved dose is 40 mg/day in Japan versus 80 mg/day
in the United States. Additionally, a 5 mg/day dose is
available in Japan. Whereas concerns regarding an in-
creased risk of statin-associated side effects relative to
Western populations appear unfounded [16], many
Japanese patients still receive a lower dose of statin [17]
and a small percentage are receiving non-statin lipid-
lowering therapy (LLT) alone [18]. The choice of LLT is
also limited because combination therapy comprising a
fibrate and a statin – which is associated with an
increased risk of rhabdomyolysis [19, 20] – should be
used with caution, and avoided among patients with
renal disorders [21]. Epidemiological studies have
shown that a substantial proportion of treated high-
risk Japanese patients do not achieve the JAS LDL-C
therapeutic targets [18, 22, 23]. An alternative treatment
approach is therefore necessary in patients who are un-
able to tolerate statins and are not adequately controlled
with non-statin LLTs or who are on the lowest-strength
dose of statins.
Alirocumab is a highly specific, fully human monoclo-
nal antibody to proprotein convertase subtilisin/kexin
type 9 (PCSK9), which plays a key role in low-density
lipoprotein receptor degradation. As monotherapy or in
combination with other LLT, alirocumab reduced LDL-C
by 44–72% at doses of 75–150 mg every 2 weeks (Q2W)
in patients with hypercholesterolemia, including heFH
[24–32]. The combination of a standard or higher doses
of statin plus alirocumab resulted in persistent reduc-
tions in LDL-C [24, 26, 29, 32] when administered
Q2W, but these reductions were not fully sustained
throughout the dosing interval in some patients when
alirocumab was administered every 4 weeks (Q4W)
[24, 26]. This response is likely due to a statin-induced
increase in PCSK9 concentrations [33], leading to greater
target-mediated clearance of alirocumab and a reduced
duration of effect [34]. The oral LLTs ezetimibe and
fenofibrate also appear to increase PCSK9 concentra-
tions in patients with elevated LDL-C, resulting in
increased clearance of alirocumab, but the effect is much
smaller than that observed with statins [34].
The ODYSSEY NIPPON study will explore the aliro-
cumab 150 mg Q4W regimen in Japanese patients with
hypercholesterolemia who are on the lowest-strength
dose of atorvastatin (5 mg/day) or are receiving a non-
statin LLT (including diet therapy alone). This group
represents patients who could potentially benefit from
the addition of a PCSK9 inhibitor to their current LLT
regimen. The primary objective is to demonstrate the
reduction of LDL-C by alirocumab 150 mg Q4W, or
150 mg Q2W, as add-on to the lowest-strength dose of
atorvastatin or non-statin LLT (including diet therapy
alone), in comparison with placebo after 12 weeks of
treatment. The secondary objectives are to evaluate the
effect of the two alirocumab regimens on other lipid
variables, the safety and tolerability of alirocumab, the
development of anti-alirocumab antibodies, the pharma-
cokinetic and pharmacodynamic profiles of alirocumab,
and the long-term safety in patients receiving open-label
alirocumab.
Methods
ODYSSEY NIPPON is a randomized, double-blind,
placebo-controlled, parallel-group phase 3 study in 163
patients recruited at 31 sites in Japan. The first patient
was enrolled in December 2015 and the last patient
was enrolled in October 2016 (http://clinicaltrials.gov/
NCT02584504).
Patients
Patients are eligible to participate if they are aged
≥20 years, have heFH or non-familial hypercholesterol-
emia (FH), are on the lowest-strength dose of atorva-
statin (i.e. 5 mg/day) or are receiving a non-statin therapy
(i.e. fenofibrate, bezafibrate, ezetimibe, or diet therapy
alone), and have elevated LDL-C values according to the
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JAS guidelines [2]. Eligible patients will also have one or
more documented reason that can explain why statin
therapy is not appropriate or why the lowest strength of
statin dose should not be increased (e.g. treatment-related
side effects, treatment with a CYP3A4 inhibitor, hepatic
dysfunction/disease, renal dysfunction, hypothyroidism,
glucose intolerance, diabetic nephropathy, older age and
low body weight [body mass index <18.5 kg/m2], and
physician decision). Patients on combination LLT are not
eligible for inclusion.
HeFH will be diagnosed by genotyping or clinical cri-
teria [35, 36]. Patients with heFH are eligible regardless
of whether they have a history of documented coronary
heart disease (i.e. myocardial infarction, unstable angina,
percutaneous coronary intervention, coronary artery
bypass grafting, or clinically significant coronary heart
disease diagnosed by invasive or non-invasive testing
such as coronary angiography, stress test using treadmill,
stress echocardiography or nuclear imaging). Patients
with non-FH must have a history of documented coron-
ary heart disease, or a history of documented diseases or
other risk factors classified by the JAS as primary
prevention category III (i.e. ischemic stroke, peripheral
artery disease, diabetes mellitus, chronic kidney disease,
or other risk factors) [2].
Hypercholesterolemia is defined as LDL-C ≥ 100 mg/dL
(2.6 mmol/L) in patients with heFH or in patients
with non-FH who have a history of documented
coronary heart disease, or ≥120 mg/dL (3.1 mmol/L)
in patients with non-FH classified as primary preven-
tion category III [2].
Study design
The study consists of five periods, illustrated in Fig. 1.
During the 4-week run-in, patients will receive stable
treatment with atorvastatin 5 mg/day, or non-statin
LLTs (ezetimibe, fenofibrate, or bezafibrate), or diet ther-
apy alone, per the physician’s decision. Patients who
have already received stable LLT, as described, for
≥4 weeks will be able to enter the screening period dir-
ectly. During the 3-week screening period, patients or a
designated person (e.g. a spouse or relative, if the patient
cannot perform the injection) will be trained for self-
injection/injection, when necessary. Patients will be
instructed to remain on a stable dose of atorvastatin
(5 mg/day) or non-statin LLT (ezetimibe, fenofibrate, or
bezafibrate) and on a stable diet (JAS guidelines [2] or
equivalent) for the study duration, from screening on-
wards. Other LLTs, including red yeast rice, other
fibrates, ethyl icosapentate, and niacin and bile acid
sequestrants are not allowed.
During the 12-week double-blind treatment period,
patients will be randomized using a 1:1:1 permuted
block design to receive alirocumab subcutaneously (SC)
150 mg Q4W alternating with placebo for alirocumab
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Fig. 1 Study design. JAS, Japan Atherosclerosis Society [2]; LDL-C, low-density lipoprotein cholesterol; LLT: lipid-lowering therapy; PCV, phone-call
visit; Q2W: every 2 weeks; Q4W: every 4 weeks; R, randomization; W, week. a As a general rule, patients start the run-in period to reach a stable daily
dose of atorvastatin 5 mg or non-statin LLT. b When patients have received atorvastatin 5 mg/day or non-statin LLT at a stable daily dose for at least
4 weeks, they can skip the run-in period and start the study from the screening period. c To maintain the double blind, injections of placebo will be
conducted at W2, W6, and W10. d Uptitration to alirocumab 150 mg Q2W at W24 is done only if LDL-C is ≥100 mg/dL or ≥120 mg/dL at W20,
depending on risk category. e Last administration of up-titrated alirocumab 150 mg Q2W at W62. f The permitted atorvastatin at a dose of 5 mg daily,
non-statin LLT, or diet therapy should remain stable (including dose) throughout the study barring exceptional circumstances
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for alirocumab Q2W. Injections of study medication
(in a 1-mL volume) will be administered by autoinjector
into the abdomen, thigh, or outer area of upper arm.
Randomization will be stratified according to background
statin therapy (Yes/No). “No statin background” will be
further stratified by background fibrate/ezetimibe therapy
(Yes/No), where ‘Yes’ represents fibrate or ezetimibe,
and ‘No’ represents diet therapy alone. All investigational
medicinal product (IMP) injections will be conducted by
site staff, patients, or designated persons. From week 0 to
week 10, all injections will be conducted at the study
site by staff or patient/designated person under direct
supervision of the staff. From week 12, during the
open-label treatment period, all injections can be con-
ducted by patients/designated persons at home if patients
agree. Otherwise, they will be conducted by the staff or
patients during predefined site visits.
The open-label treatment period will last for 52 weeks,
during which all patients will receive alirocumab 150 mg
SC Q4W (Fig. 1). At week 24, a dose increase of alirocu-
mab to 150 mg SC Q2W will be automatically con-
ducted through the interactive web response system in
patients with heFH or non-FH with documented coron-
ary heart disease if LDL-C is ≥100 mg/dL (2.6 mmol/L)
at week 20, and in non-FH category III patients if LDL-
C is ≥120 mg/dL (3.1 mmol/L) at week 20. Patients will
be followed for 8 weeks after completion of the open-
label treatment period.
Key study endpoints and assessments
The primary efficacy endpoint is the percentage change in
calculated LDL-C from baseline to week 12 in the
intention-to-treat (ITT) population. The key secondary ef-
ficacy endpoints include the change from baseline to week
12 in other atherogenic lipoproteins, listed in Table 1.
Lipid variables will be assessed at 0, 4, 8, 10, and 12 weeks
(end of double-blind treatment period), and at 20, 24, 36,
48, and 64 weeks (end of open-label treatment period).
The laboratory measurement of lipid parameters will be
performed by a central laboratory. To maintain the blind,
values obtained during the double-blind treatment period
will not be communicated to the investigator or sponsor.
LDL-C will be calculated using the Friedewald formula
[37]. If triglyceride values exceed 400 mg/dL (4.5 mmol/
L), the central laboratory will automatically measure LDL-
C via the beta-quantification method.
The endpoints related to evaluation of the safety and
tolerability of alirocumab and the development of anti-
alirocumab antibodies will be assessed throughout the
study. The safety endpoint (comprising adverse events
[including adjudicated cardiovascular events], laboratory
data, and vital signs) will be analyzed by a central labora-
tory. The evaluation of anti-alirocumab antibodies will
include the antibody status (positive or negative) and
antibody titers. Anti-alirocumab antibodies will be de-
termined by the Regeneron Clinical Bioanalysis group
(Regeneron Pharmaceuticals Inc. Tarrytown, NY, USA)
using a validated non-quantitative, titer-based bridging
immunoassay.
Statistical design and analyses
Sample size consideration
Two pairwise comparisons will be performed (alirocu-
mab 150 mg Q4W versus placebo and alirocumab
150 mg Q2W vs placebo) using Bonferroni adjustment
to handle multiplicity. A sample size of 38 patients in
the ITT population (19 in alirocumab group and 19 in
placebo group) was calculated to have 90% power to
detect a difference of 30% in mean percent change in cal-
culated LDL-C in any pairwise comparison with a 0.025
Table 1 Key secondary efficacy endpoints (in hierarchical order)
1. The percentage changes in calculated LDL-C from baseline to week
12 in the mITT population, using all LDL-C values during the efficacy
double-blind treatment period (on-treatment estimand).
2. The percentage change in calculated LDL-C from baseline to average
week 10–12 (ITT estimand).
3. The percentage change in calculated LDL-C from baseline to average
week 10–12 (on-treatment estimand).
4. The percentage change in Apo-B from baseline to week 12 (ITT
estimand).
5. The percentage change in Apo-B from baseline to week 12 (on-treat-
ment estimand).
6. The percentage change in non-HDL-C from baseline to week 12
(ITT estimand).
7. The percentage change in non-HDL-C from baseline to week 12
(on-treatment estimand).
8. The percentage change in TC from baseline to week 12 (ITT estimand).
9. The proportion of patients reaching LDL-C goal at week 12, i.e.
calculated LDL-C < 100 mg/dL (2.6 mmol/L) for heFH or non-FH
patients who have a history of documented CHD patients, or
LDL-C < 120 mg/dL (3.1 mmol/L) for non-FH patients who have a
history of documented diseases or other risk factors classified as primary
prevention category III (ITT estimand).
10. The proportion of patients reaching LDL-C goal at week 12, i.e.
calculated LDL-C < 100 mg/dL (2.6 mmol/L) for heFH or non-FH patients
who have a history of documented CHD patients, or LDL-C < 120 mg/
dL (3.1 mmol/L) for non-FH patients who have a history of documented
diseases or other risk factors classified as primary prevention category III
(on-treatment estimand).
11. The percentage change in lipoprotein(a) from baseline to week 12
(ITT estimand).
12. The percentage change in HDL-C from baseline to week 12
(ITT estimand).
13. The percentage change in fasting triglyceride from baseline to week
12 (ITT estimand).
14. The percentage change in Apo A-1 from baseline to week 12
(ITT estimand).
Apo apolipoprotein, CHD coronary heart disease, FH familial
hypercholesterolemia, HDL-C high-density lipoprotein cholesterol, heFH heterozy-
gous familial hypercholesterolemia, ITT intent-to-treat, LDL-C low-density lipopro-
tein cholesterol, mITTmodified intent-to-treat, TC total cholesterol
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two-sided significance level and assuming a common
standard deviation of 25%. The total sample size for effi-
cacy would therefore be 57 patients (19 in each of the
alirocumab arms and 19 in the placebo arm).
With the sample size consideration for the long-term
safety profile, the overall study sample size is 159 patients,
allocating 53 patients to alirocumab 150 mg Q4W, 53
patients to alirocumab 150 mg Q2W, and 53 patients to
placebo. With this sample size, 100 patients are expected
to be exposed to alirocumab for a minimum of 12 months
providing that the proportion of dropout is 36%, which is
obtained using exponential distribution with the same
hazard as that of 30% dropout rate within 12 months.
With 100 patients treated with alirocumab for at least
12 months, adverse events with a rate ≥ 0.03 will be
detected with 95% probability. Therefore, 159 patients are
needed to evaluate both efficacy and safety (163 patients
were actually recruited).
Efficacy analyses
The randomized population will include all patients who
have been allocated to a randomized treatment regard-
less of whether they received the study medication. The
primary efficacy analysis population will be the ITT
population, defined as the randomized population who
has an evaluable primary efficacy endpoint (i.e. patients
with at least one value for calculated LDL-C before the
first double-blind dose [i.e. baseline] and at least one
value for calculated LDL-C for weeks 4, 8, 10, or 12).
The modified ITT (mITT) population is defined as the
randomized population who took at least one dose or
partial dose of the double-blind injection and had an
evaluable primary efficacy endpoint during the efficacy
double-blind treatment period, defined as the period
from the first double-blind IMP injection up to 21 days
after the last double-blind IMP injection. Patients will be
analyzed according to the treatment group allocated by
randomization.
The primary efficacy endpoints will be analyzed in the
ITT population using a mixed-effect model with re-
peated measures (MMRM) approach. The model will
include the fixed categorical effects of treatment group,
time point (4, 8, 10, 12 weeks), stratification factor of
statin (Yes/No), treatment-by-time-point interaction and
statin-by-time-point interaction, as well as the continu-
ous fixed covariates of baseline calculated LDL-C value,
and baseline value-by-time-point interaction. This model
is used to provide baseline adjusted least square (LS)
mean estimates at week 12 for each treatment group
with their corresponding standard errors. Each alirocu-
mab group will be compared to the placebo group (at
significance level of 2.5%) using appropriate contrasts,
and the 97.5% confidence interval of the difference will
be provided. Subgroup analyses will be performed to
assess the consistency of treatment effect within stratifi-
cation factor of statin (Yes/No).
Continuous secondary endpoints anticipated to have a
normal distribution will be analyzed using the same
MMRM model as for the primary endpoint with the con-
tinuous fixed covariates of corresponding baseline value
and baseline value-by-time-point interaction. Those antic-
ipated to have a non-normal distribution (i.e. lipo-
protein[a] and triglycerides) will be analyzed using a
multiple imputation approach for handling of missing
values followed by robust regression. Binary secondary
endpoints will be analyzed using a multiple imputation
approach for handling of missing values followed by logis-
tic regression. In the data-dependent case that the logistic
regression method is not applicable (e.g. the response rate
is zero in one treatment arm and thus the maximum like-
lihood estimate may not exist), the last observation carried
forward approach would be used for handling of missing
values and a stratified exact conditional logistic regression
would be performed to compare treatment effects.
A hierarchical procedure will be used for each pairwise
comparison to control type I error and to handle mul-
tiple endpoints. If the primary endpoint analysis is
significant at the 2.5% alpha level, the key secondary effi-
cacy endpoints will be tested sequentially at the 0.025
level, using the order defined in Table 1. The hierarch-
ical procedure for comparisons of alirocumab 150 mg
Q4W versus placebo and alirocumab 150 mg Q2W
versus placebo will be processed separately. Analyses
conducted in the open-label treatment period will be
exploratory only.
Safety analysis
The safety analysis will be descriptive. The safety popula-
tion will comprise the randomized population who re-
ceived at least one dose or partial dose of study
medication, and will be analyzed according to the treat-
ment received.
Discussion
An unmet medical need exists for additional, efficacious,
and well-tolerated therapeutic options in patients with
hypercholesterolemia who exhibit an inadequate lipid-
lowering response to current therapies or who are un-
able to take standard or higher doses of statins because
of side effects, contraindications, or for other reasons.
The efficacy and safety of alirocumab have been inves-
tigated in Japanese populations in phase 1 and 2 studies
[38]; their results were confirmed in a 52-week Japanese
phase 3 study involving 216 high-risk adults (defined as
heFH, non-FH at high cardiovascular risk with coronary
disease, or classified as category III) [39] treated with
75 mg Q2W with the potential for titration to 150 mg
Q2W at week 12 if the LDL-C target was not met at
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week 8. At week 24, mean change in LDL-C from base-
line was −62.5% in the alirocumab group versus 1.6% in
the placebo group (P < 0.0001) with a dose increase to
150 mg Q2W in only 1.4% of patients; the reduction was
sustained to week 52 [39]. Combined, the results of these
studies show that alirocumab significantly reduced LDL-C
concentrations versus placebo in high-risk Japanese pa-
tients on stable statin therapy with or without other LLTs
and was generally well tolerated. The most frequently
reported adverse events were nasopharyngitis (45.5% in
the alirocumab group versus 36.1% in the placebo group),
back pain (12.6% vs 5.6%, respectively), and injection site
reaction (12.6% vs 4.2%, respectively).
A randomized, placebo-controlled, phase 1 study –
conducted outside of Japan – investigated ascending
doses of alirocumab in patients with and without FH
(50, 100, 150 mg) [40]. The study included three cohorts:
the first involved 21 patients with heFH on atorvastatin
therapy; the second cohort included 30 non-FH patients,
also on atorvastatin therapy; whereas the third cohort of
10 patients with non-FH were being treated with diet-
therapy alone. With the 150 mg dose of alirocumab,
2 weeks after the first administration, the mean differ-
ence in percent change in LDL-C from baseline, versus
placebo, was at least 46% in all three cohorts. The effects
of alirocumab and atorvastatin in lowering LDL-C ap-
peared to be additive, as the mean percent reductions
were similar in the three cohorts; however, they were
not fully maintained over the dosing period in patients
already receiving a statin. The “bounce back” in LDL-C
value observed in the statin-treated cohort is likely due
to the fact that statins stimulate the production of
PCSK9; while this does not alter the LDL-lowering effect
of alirocumab, it appears to reduce the duration of ac-
tion [34]. In contrast, the reduction in LDL-C was con-
sistent over the dosing period in the patients treated
with diet-therapy alone, suggesting that alirocumab has
a longer duration of action in the absence of a statin.
Ezetimibe and fenofibrate also appear to increase
PCSK9 concentrations, but the effect is much less sub-
stantial than that with statins [34]. This finding is illus-
trated in a partial-blinded French study involving 72
patients with LDL-C levels ≥100 mg, randomized to
once-daily oral dosing with fenofibrate 160 mg, ezeti-
mibe 10 mg, or placebo, plus alirocumab 150 mg Q4W
for 3 months [34]. The mean reductions in LDL-C with
alirocumab plus placebo were maintained over the 4-
week dosing interval (percent change from baseline:
44.4% at day 57, 47.4% at day 71, and 47.0% at day 85).
Whereas greater reductions in LDL-C were achieved
with the combination LLT (65.3% with ezetimibe and
66.8% with fenofibrate, versus 48.2% with placebo, at day
71, 2 weeks after the last dose), the PCSK9 levels and
the alirocumab clearance rate were increased, and the
efficacy was slightly less sustained between drug admin-
istrations with the combination LLT (49.6% with ezeti-
mibe and 43.2% with fenofibrate at day 85, 4 weeks after
the last dose). The alirocumab 150 mg Q4W regimen
could therefore provide ongoing and efficacious reduc-
tions in LDL-C over a 4-week dosing interval when ad-
ministered as monotherapy or in combination with non-
statin LLT [34]. This dosing regimen might be a preferred
option in some patients.
Two phase 3 studies have evaluated the Q4W aliro-
cumab regimen, in predominantly white populations.
ODYSSEY CHOICE II [41] followed a ‘treat-to-target’
dosing strategy, and evaluated the efficacy and safety of
alirocumab 150 mg Q4W (with possible adjustment to
150 mg Q2W) in patients with hypercholesterolemia not
receiving statin therapy. Most of the study population
(90.1%) had a history of intolerable statin-associated
muscle symptoms. The alirocumab 150 mg Q4W regi-
men led to LDL-C reductions from baseline of −41.7%
at week 12, suggesting that this strategy may be an add-
itional therapeutic option in Japan for patients with
hypercholesterolemia not on statin therapy, and notably
for those intolerant of statin treatment. However, this
dosing strategy may not provide adequate LDL-C reduc-
tion in all patients, for example, those receiving con-
comitant statin or those with higher baseline LDL-C
levels. ODYSSEY CHOICE I investigated the efficacy,
long-term safety, and tolerability of an alirocumab
300 mg Q4W regimen, with dose adjustment at week 12
to 150 mg Q2W depending on individual patient re-
sponse, as add-on to statin therapy or monotherapy in
moderate to very high risk patients with hypercholester-
olemia [42]. This alirocumab regimen showed statisti-
cally significant reductions from baseline in LDL-C in
patients receiving and not receiving concomitant statin,
with no increase in treatment-emergent adverse events
across the study groups. At week 24, a reduction of
−52.7% was achieved with alirocumab 300 mg Q4W in
patients not receiving statin (14.7% of whom had dose
adjustment to 150 mg Q2W) and of −58.8% in patients
receiving concomitant statin therapy (19.3% of whom
had dose adjustment) [42].
Conclusions
The data from the ODYSSEY NIPPON study will pro-
vide insights into the efficacy and safety of alirocumab
150 mg Q4W or 150 mg Q2W among Japanese patients
with hypercholesterolemia who are on the lowest-
strength dose of statin, or are receiving a non-statin LLT
(including diet therapy alone). This group of patients
could potentially achieve lower LDL-C levels with the
addition of a PCSK9 inhibitor to their current LLT
regimen using a monthly dosing regimen.
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